Floatz logo

Prednisone

Respiratory Tract Infectious Disorder

Explore 2 assets in Respiratory Tract Infectious Disorder →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Maisonneuve-Rosemont Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT01432080CT.gov
Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Respiratory Tract Infectious Disorder

AssetSponsorPhaseRating
Prednisone (this asset)Maisonneuve-Rosemont HospitalP2CCC · 53
PiperacillinChronic Obstructive Pulmonary Disease Trial Network, DenmarkP4BB
TazobactamChronic Obstructive Pulmonary Disease Trial Network, DenmarkP4BB
CiprofloxacinChronic Obstructive Pulmonary Disease Trial Network, DenmarkP4B
AzithromycinMaisonneuve-Rosemont HospitalP2CCC
SymbicortMaisonneuve-Rosemont HospitalP2CCC
MontelukastMaisonneuve-Rosemont HospitalP2CCC
MurepavadinPolyphor Ltd.P2CCC
XENONMario Castro, MD, MPHP1CC

+5 more in the Respiratory Tract Infectious Disorder cohort

Other indications for Prednisone

IndicationSponsorPhaseRating
B-Cell Childhood Acute Lymphoblastic Leukemia—P3BBB · 74
Diffuse Large B-Cell Lymphoma—P4BBB · 74
Peripheral T-Cell Lymphoma, Not Otherwise Specified—P4BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Prednisone in Respiratory Tract Infectious Disorder. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/prednisone-respiratory-tract-infectious-disorder

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →